BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 30c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.66), $0.30 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $54.02 million versus the consensus estimate of $29.12 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley more than doubles Lenovo price target on AI-driven growth
• Occidental Petroleum releases Q2 2026 earnings considerations